What is the history of Eales Disease?

Eales disease is an idiopathic inflammatory venous occlusion of the retina that was first described by Henry Eales in 1880, initially characterized as retinal hemorrhages associated with constipation and epistaxis in young men. Since its discovery, medical understanding has evolved from viewing Eales disease as a systemic vascular disorder to a complex, likely immune-mediated condition linked to latent tuberculosis infection.

Who first discovered Eales disease?

The condition was first identified by Henry Eales, a British ophthalmologist, who presented his findings to the Ophthalmological Society of the United Kingdom in 1880. He observed a specific pattern of recurring retinal hemorrhages in young, otherwise healthy men. While Eales initially hypothesized that the condition was linked to vasomotor disturbances, the medical community eventually moved away from his early theories as diagnostic technology advanced.

How has our understanding of Eales disease evolved?

For decades, Eales disease was considered a diagnosis of exclusion. A major turning point in the history of the disease was the identification of a strong association between Eales disease and hypersensitivity to tuberculoprotein, particularly in regions like India. While the exact etiology remains debated, modern research suggests that Eales disease involves an inflammatory process where the body’s immune system reacts to mycobacterial antigens, leading to peripheral retinal periphlebitis and subsequent neovascularization.

What are the major historical milestones in treatment?

Treatment for Eales disease has shifted from observation and systemic steroids to targeted surgical and laser interventions. Key historical milestones include:

• Early 20th Century: Reliance on systemic corticosteroids to manage inflammation.


• 1970s-1980s: The introduction of photocoagulation, which revolutionized the management of retinal neovascularization.


• Modern Era: The use of anti-VEGF (vascular endothelial growth factor) agents to treat macular edema and prevent vision loss.


• Surgical Advances: Pars plana vitrectomy becoming the gold standard for treating non-clearing vitreous hemorrhages caused by Eales disease.

How has patient advocacy changed?

Historically, patients with Eales disease often felt isolated due to the rarity of the condition. Today, platforms like DiseaseMaps.org connect the 23 community members currently registered, allowing for the sharing of lived experiences and navigation of complex treatment paths. This collective knowledge helps demystify the condition and supports those facing the uncertainty of vision-threatening symptoms.

Next steps

• Consult a retina specialist or ophthalmologist experienced in inflammatory eye diseases.


• Undergo testing for latent tuberculosis, as this is a clinically significant factor in many cases.


• Join the DiseaseMaps.org community to connect with others who have been diagnosed with Eales disease.

Medical disclaimer: This information is for educational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician.

References

• NIH Genetic and Rare Diseases Information Center (GARD)


• Orphanet: Portal for rare diseases and orphan drugs


• PubMed: Clinical reviews on the pathogenesis of retinal periphlebitis


• American Academy of Ophthalmology: Clinical guidelines for peripheral retinal vascular diseases